The present invention addresses the problem of providing a tablet that contains a high concentration of acetaminophen, satisfies an acetaminophen dissolution rate from the tablet of at least 80% in 15 minutes, and can be manufactured by dry direct compression. The present invention provides a tablet including: acetaminophen that has a median particle diameter in a range from 100 to 350 µm; crystalline cellulose that has a bulk density in a range from 0.10 to 0.23 g/cm3; and at least two types of disintegrants. The at least two types of disintegrants are (a) at least one disintegrant selected from the group consisting of crospovidone, croscarmellose sodium, and sodium starch glycolate, and (b) a disintegrant that is a low-substituted hydroxypropyl cellulose. The acetaminophen content per tablet is at least 86 weight%.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention addresses the problem of providing a tablet that includes a high concentration of acetaminophen, that elutes acetaminophen at a rate of at least 80% in fifteen minutes, and that can be manufactured by dry tableting. The present invention provides a tablet, containing acetaminophen with a median grain diameter in the range 100–350 μm, crystalline cellulose with a bulk density in the range 0.10–0.23 g/cm3, and disintegrants of at least two types, wherein: the disintegrants of at least two types are a disintegrant (a) of at least one type selected from the group consisting of crospovidone, croscarmellose sodium, and sodium starch glycolate, and a disintegrant (b) that is low-substituted hydroxypropylcellulose; and the acetaminophen content per tablet is at least 86% by weight.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.
The present invention addresses the problem of providing an orally disintegrating tablet that includes acetaminophen at a high concentration of 75mass% or more, while having a tablet hardness of 50N or more and having a useful quick oral disintegration property. The present invention provides an orally disintegrating tablet including: acetaminophen with a median grain size in the range 80-300μm; a highly moldable crystalline cellulose; and a disintegrant, wherein the acetaminophen content by percent in one tablet is 75mass% or more, the acetaminophen content by quantity in one tablet is 190mg or more, and the orally disintegrating tablet has a tablet hardness of 50N or more.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
[Problem] To provide a therapeutic agent for Wolfram syndrome. [Solution] A therapeutic agent for Wolfram syndrome that comprises a calcineurin inhibitor as an active ingredient, wherein the calcineurin inhibitor is cyclosporine, tacrolimus, rapamycin, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate of the same.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
A61K 31/428 - Thiazoles condensed with carbocyclic rings
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined in the description) or a pharmaceutically acceptable salt thereof.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]:
3 are the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.
A method for treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-hydroquinoline compound.
A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator.
8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; Z represents a chalcogen atom; and P represents 0, 1, 2 or 3.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; medicines for human purposes;
vitamin preparations; medicinal drinks; ointments for
pharmaceutical purposes; antibiotics; steroids; radioactive
substances for medical purposes; oxygen baths; sterilising
preparations; solutions for contact lenses; preparations of
microorganisms for medical and veterinary use; antirheumatic
agents; antiarthrists agents; veterinary preparations;
diagnostic preparations for medical purposes; plasters for
medical purposes; disinfectants for hygiene purposes,
antiseptics; vermin destroying preparations; fungicides,
herbicides; detergents for medical purposes; antiparasitic
collars for animals.
The purpose of the present invention is to find a substance capable of inhibiting the production of IL-2. The production of IL-2 can be inhibited with a compound represented by general formula (I) (wherein R1 to R4 and A are as defined in the description) or a pharmaceutically acceptable salt thereof.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
This 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative or a salt thereof has BRD4 inhibitory activity and is therefore useful as a drug, especially as an agent to prevent and/or treat diseases involving BRD4.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
